Gilead to buy East Coast breast cancer-focused biotech in $21 billion deal

New Jersey-based Immunomedics' stock jumped 98% midday Monday to $84 per share after the announcement of Gilead's cash offer, which represents a 108% premium to Immunomedics’ closing price on Friday.

Click to view original post